Replies to post #170217 on Avid Bioservices Inc (CDMO)

[keep_trying]

EBS, having the research funds in the hands of an independent party on track to validate science behind PS targeting is a good thing for PPHM, IMO. Remember when critiques on this board were flagging concern about there not being buzz in the research community. I hear buzzing now, don't you?

Best wishes and IMO,
KT

[biopharm]

I can see your point on one side but the flip side is this looks to be one of the ways that "Bavi" will get into the hands of as many as possible and Peregrine does not need to pay one dime to those researchers/scientists that are investigating PS targeting.

Further, Peregrine/Avid will be most likely manufacturing the drugs for their research (this one being Dengue fever) so it will be interesting in what will be used-- Bavi? beta bodies..or something else under wraps? and overall this creates more to the bottom line profits.

What happens when these 20...30...40... or more? researchers start to realize the wonders that Bavituximab and PS targeting possesses? I'd say collaboration deals will closing faster as they progress...

The part that I like is Big Pharma "DOES NOT" want PS targeting to reach global development type status, because its too late to hold it back at that point. The only way Big Pharma has "any" control on holding it back "some" is if they just pay the piper and it will cost them big time to do so. I'm sure Paul Lytle will be smiling at that point and SK will be thanking Abbott for not having faith in the Phase IIb NSCLC results.

Pay up and they can somewhat control the "global development" and will those offers become public? I bet a lot of preferred shares @ $25 for a total of 4.3M shares and a grand total of $107M+ in the coffers for Peregrine--- can all be sold into that type of leak..

time will tell...